Providence Capital Advisors, LLC Amgen Inc Transaction History

Providence Capital Advisors, LLC

$487 Million
Q3 2024

A detailed history of Providence Capital Advisors, LLC transactions in Amgen Inc stock. As of the latest transaction made, Providence Capital Advisors, LLC holds 3 shares of AMGN stock, worth $840. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 48 93.75%

Holding current value

$840

Previous $14,000 100.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$309.38 - $337.38 $13,922 - $15,182	-45 Reduced 93.75%	3 $0
Q2 2024 Aug 14, 2024	BUY	$262.75 - $319.31 $788 - $957	3 Added 6.67%	48 $14,000
Q1 2024 May 13, 2024	SELL	$268.87 - $324.56 $17,745 - $21,420	-66 Reduced 59.46%	45 $12,000
Q3 2023 Nov 13, 2023	BUY	$218.65 - $271.46 $24,270 - $30,132	111 New	111 $29,000
Q2 2022 Aug 09, 2022	SELL	$230.71 - $256.74 $23,532 - $26,187	-102 Reduced 80.31%	25 $6,000
Q1 2022 May 12, 2022	SELL	$219.27 - $242.57 $22,146 - $24,499	-101 Reduced 44.3%	127 $30,000
Q4 2021 Feb 11, 2022	SELL	$198.88 - $227.6 $30,627 - $35,050	-154 Reduced 40.31%	228 $51,000
Q3 2021 Nov 09, 2021	BUY	$212.27 - $248.7 $81,087 - $95,003	382 New	382 $81,000
Q1 2021 May 13, 2021	SELL	$221.91 - $258.6 $14,646 - $17,067	-66 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$216.38 - $257.67 $14,281 - $17,006	66 New	66 $15,000
Q2 2020 Aug 04, 2020	SELL	$197.81 - $242.74 $45,298 - $55,587	-229 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$182.24 - $241.7 $41,732 - $55,349	229 New	229 $47,000
Q3 2019 Nov 13, 2019	SELL	$174.11 - $208.62 $522 - $625	-3 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$166.7 - $195.41 $500 - $586	3 New	3 $1,000

Others Institutions Holding AMGN

# of Institutions

3,123

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $150B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Providence Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Providence Capital Advisors, LLC with notifications on news.

Account

Providence Capital Advisors, LLC Amgen Inc Transaction History